Lexeo Therapeutics
Lexeo Therapautics is a gene-therapy biotechnology company developing treatments for genetically defined cardiovascular and central nervous system diseases.
Lexeo Therapeutics' treatments function by utilizing adeno-associated viruses (AAVs) to transfer specific therapeutic genes to patients. The company is focused on hereditary and acquired diseases such as Friedreich’s ataxia, Batten disease (CLN2) and Alzheimer’s disease (APOE4).
